AgNovos Bioscience Email Format

Medical Equipment ManufacturingMaryland, United States11-50 Employees

AgNovos Healthcare develops therapies for bone disease by applying proprietary bone-building technology alongside regenerative medicine approaches. Its lead product, the OSSURE Local Osteo-Enhancement Procedure (LOEP) kit, has been evaluated in multiple clinical studies and is marketed in select markets. The company is privately held, with corporate headquarters in New York City and manufacturing, research and development, and support services based in Rockville, Maryland.

RESTORE is a randomized, controlled, prospective, single-blinded, multinational trial designed to assess whether OSSURE LOEP reduces the risk of secondary hip fractures in osteoporotic women treated for an index fracture, and is among the larger studies in orthopedic trauma. A second LOEP device, AGN1 LOEP SV kit, targets stable but painful vertebral compression fractures and has received FDA Breakthrough Device designation and an IDE. Data from these efforts are intended to support broader access to the company’s therapies in markets that include the United States and Japan.

Get verified AgNovos Bioscience emails free

Company overview Employee directory